89 related articles for article (PubMed ID: 7277091)
1. Profiles of psychedelic drugs: 10. DOB.
Shulgin A
J Psychoactive Drugs; 1981; 13(1):99. PubMed ID: 7277091
[No Abstract] [Full Text] [Related]
2. [3H]DOB: a specific agonist radioligand for 5-HT2 serotonin receptors.
Titeler M; Herrick K; Lyon RA; McKenney JD; Glennon RA
Eur J Pharmacol; 1985 Oct; 117(1):145-6. PubMed ID: 4085543
[No Abstract] [Full Text] [Related]
3. Potent agonist activity of DOB at 5-HT2 receptors in guinea pig trachea.
Heller WA; Baraban JM
Eur J Pharmacol; 1987 Jun; 138(1):115-7. PubMed ID: 3622603
[TBL] [Abstract][Full Text] [Related]
4. A reevaluation of psychotomimetic amphetamine derivatives in humans.
Cassels BK; Gómez-Jeria JS
J Psychoactive Drugs; 1985; 17(2):129-30. PubMed ID: 4020537
[No Abstract] [Full Text] [Related]
5. The effects of 2,5-dimethoxy-4-methylamphetamine (DOM) on operant behavior: interactions with other neuroactive agents.
Commissaris RL; Semeyn DR; Moore KE; Rech RH
Commun Psychopharmacol; 1980; 4(5):393-404. PubMed ID: 6120791
[No Abstract] [Full Text] [Related]
6. [Studies on the identification of psychotropic substances. VI. Preparation and various analytical data of reference standards of some hallucinogens, 2,5-dimethoxy-4-methylamphetamine (STP), 2,5-dimethoxy-4-bromoamphetamine (DOB) and 2,5-dimethoxy-4-ethylamphetamine (DOET)].
Shimamine M; Takahashi K; Nakahara Y
Eisei Shikenjo Hokoku; 1989; (107):113-9. PubMed ID: 2636911
[TBL] [Abstract][Full Text] [Related]
7. Abuse potential of methylenedioxymethamphetamine (MDMA) and its derivatives in zebrafish: role of serotonin 5HT2-type receptors.
Ponzoni L; Braida D; Sala M
Psychopharmacology (Berl); 2016 Aug; 233(15-16):3031-9. PubMed ID: 27318987
[TBL] [Abstract][Full Text] [Related]
8. Congeners of DOM: effect of distribution of the evaluation of pharmacologic data.
Barfknecht CF; Caputo JF; Tobin MB; Dyer DC; Standirdge RT; Howell HG; Goodwin WR; Partyka RA; Gylys JA; Cavanagh RL
NIDA Res Monogr; 1978; (22):16-26. PubMed ID: 101880
[No Abstract] [Full Text] [Related]
9. A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: a potential drug of abuse.
Glennon RA; Titeler M; Lyon RA
Pharmacol Biochem Behav; 1988 Jul; 30(3):597-601. PubMed ID: 3211969
[TBL] [Abstract][Full Text] [Related]
10. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex.
Pierce PA; Peroutka SJ
Psychopharmacology (Berl); 1989; 97(1):118-22. PubMed ID: 2540505
[TBL] [Abstract][Full Text] [Related]
11. Phenethylamine hallucinogens in the locus coeruleus: potency of action correlates with rank order of 5-HT2 binding affinity.
Rasmussen K; Glennon RA; Aghajanian GK
Eur J Pharmacol; 1986 Dec; 132(1):79-82. PubMed ID: 3816969
[TBL] [Abstract][Full Text] [Related]
12. Choroid plexus epithelial cells in primary culture: a model of 5HT1C receptor activation by hallucinogenic drugs.
Sanders-Bush E; Breeding M
Psychopharmacology (Berl); 1991; 105(3):340-6. PubMed ID: 1665919
[TBL] [Abstract][Full Text] [Related]
13. The behavioral effects of 2,5-dimethoxy-4-alkyl amphetamines.
Morin RD; Benington F; Mitchell SR; Beaton JM; Bradley RJ; Smythies JR
Experientia; 1975 Jan; 31(1):93-5. PubMed ID: 234850
[No Abstract] [Full Text] [Related]
14. Evaluation of substituted-amphetamine hallucinogens using the cat limb flick model.
Rusterholz DB; Spratt JL; Long JP; Barfknecht CF
Commun Psychopharmacol; 1977; 1(6):589-92. PubMed ID: 608329
[No Abstract] [Full Text] [Related]
15. Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents.
Glennon RA; Rosecrans JA; Young R
Med Res Rev; 1983; 3(3):289-340. PubMed ID: 6350763
[No Abstract] [Full Text] [Related]
16. Hallucinogenic and stimulatory amphetamine derivatives: fingerprinting DOM, DOI, DOB, MDMA, and MBDB by spectral analysis of brain field potentials in the freely moving rat (Tele-Stereo-EEG).
Dimpfel W; Spüler M; Nichols DE
Psychopharmacology (Berl); 1989; 98(3):297-303. PubMed ID: 2568652
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran ("FLY") and benzodifuran ("DragonFLY") analogs.
Halberstadt AL; Chatha M; Stratford A; Grill M; Brandt SD
Neuropharmacology; 2019 Jan; 144():368-376. PubMed ID: 30385253
[TBL] [Abstract][Full Text] [Related]
18. Indolealkylamine and phenalkylamine hallucinogens. Effect of alpha-methyl and N-methyl substituents on behavioral activity.
Glennon RA; Young R; Jacyno JM
Biochem Pharmacol; 1983 Apr; 32(7):1267-73. PubMed ID: 6573879
[TBL] [Abstract][Full Text] [Related]
19. LSD or DOB?
Davis WM
Am J Psychiatry; 1982 Dec; 139(12):1649. PubMed ID: 7149079
[No Abstract] [Full Text] [Related]
20. The 5-hydroxytryptamine2 agonist, (+-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. II. Biochemical and physiological evidence for the development of tolerance after chronic administration.
Owens MJ; Knight DL; Ritchie JC; Nemeroff CB
J Pharmacol Exp Ther; 1991 Feb; 256(2):795-800. PubMed ID: 1847213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
